PYRUVATE KINASE ISOFORM M2 AS A DIAGNOSTIC TOOL FOR RENAL CELL CARCINOMA
Ibrahim El Tantawy El Sayed*, Sally Mohammed El-Hefnway, Alshimaa Mahmoud Alhanafy and Khadiga Mohamed Sallam
Renal cell carcinoma (RCC) is the most common cancer in the kidney. Pyruvate kinase is an enzyme that catalyzes the conversion of phosphoenol pyruvate and ADP to pyruvate and ATP in glycolysis. Aim of the study: The current study was conducted to evaluate pyruvate kinase M2 (PKM2) level in serum as a tumor marker in renal cell carcinoma. Subjects and Methods: serum PKM2 level of 120 patients with RCC and 80 healthy volunteers was detected by ELISA, and correlated with tumor stage and grade. Results: serum PKM2 level was significantly higher in RCC group than in control groups. There was a significant positive correlation between PKM2 and both of tumor stage and grade. ROC curve revealed that, at a cut -off point of (2.27 ng/ml), the sensitivity of PKM2 in diagnosis of renal cancer was 70%, the specificity was 68.27%, and accuracy of the test was 66.46%. Conclusions: Serum PKM2 could be considered as a diagnostic marker for RCC.
Hypertension and diabetes are risk factors for development of RCC
Serum PKM2 is significantly increased in RCC group when compared to controls.
Serum PKM2 may have a role in RCC staging , helping in clinical evaluation.
[Full Text Article]